Bionpharma

Bionpharma

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $20M

Overview

Bionpharma is a private, commercial-stage generic and specialty pharmaceutical company headquartered in Princeton, New Jersey. It operates a hybrid business model combining B2B activities—including generic drug development, manufacturing (notably softgel capsules), and contract services—with a direct-to-consumer e-commerce arm via its A+ Health brand on Amazon. The company's strategy is centered on providing cost-effective healthcare solutions through internal R&D and manufacturing, supported by overseas affiliates, and it is actively seeking in-licensing opportunities for the US market.

Generic Drugs

Technology Platform

Integrated generic & OTC pharmaceutical development and manufacturing platform, with specialization in softgel capsules and direct-to-consumer e-commerce via Amazon.

Funding History

1
Total raised:$20M
Series A$20M

FDA Approved Drugs

1
NAPROXEN SODIUMNDAFeb 17, 2006

Opportunities

The growing demand for affordable generic drugs and the expansion of e-commerce for OTC products present significant opportunities.
Bionpharma's softgel manufacturing expertise and its direct-to-consumer A+ Health brand on Amazon position it to capture value in these evolving market segments.

Risk Factors

Key risks include intense price competition in the generic drug market, regulatory compliance challenges with the FDA, and dependence on third-party platforms like Amazon for a portion of its revenue.
Supply chain reliance on overseas affiliates also introduces operational vulnerabilities.

Competitive Landscape

Bionpharma competes in the highly competitive generic pharmaceutical industry against large players like Teva, Sandoz (Novartis), and Mylan (Viatris), as well as numerous smaller generic firms. Its A+ Health brand competes with both established OTC brands and other digital-native healthcare brands on Amazon.